What if insulin-producing beta cells in type 1 diabetes are not dying only through the usual pathways, but through an iron-driven process that can be blocked? This study tests that possibility in diabetic mice. Regulated cell death relies on specific molecular machinery and therefore can be modulated pharmacologically or genetically.

Ferroptosis is a necrotic form of regulated cell death manifested by an iron-dependent accumulation of membrane lipid peroxides. A central problem is the depletion of glutathione, which causes failure of the lipid peroxide removal capacity of GPX4. The xCT subunit brings in L-cystine, which is converted to cysteine, a precursor of glutathione.

Cellular susceptibility to ferroptosis is triggered by imbalance between iron import, storage, and export, increasing the cytosolic labile iron pool. Nrf2 is considered a master regulator of genes related to ferroptosis, including GPX4 and SLC7a11.

Reduction of pancreatic beta-cell mass is the most important pathological feature of both type one and type two diabetes, and the main cause is considered to be cell death. Earlier descriptions emphasized apoptosis, necrosis, and autophagic regulated cell death.

The study’s earlier work confirmed ferroptosis under diabetogenic conditions in vitro, and an in vivo pilot study demonstrated ferroptosis as an important mode of beta-cell death in streptozotocin-induced type one diabetes. Fer-1 is a free-radical scavenging synthetic antioxidant that inhibits iron-dependent lipid peroxidation.

Preliminary in vivo results showed reduced lipid peroxidation, improved islet size, increased insulin expression, and fewer signs of peri-insulitis. The work aimed to elucidate the mechanisms of reduction in beta-cell mass under diabetic conditions in vivo, including characterization of the ferroptotic phenotype in situ.

It also aimed to define the benefits of ferroptosis inhibition in the endocrine pancreas under diabetic conditions. Fer-1 was selected, and a thorough microscopic examination of pancreatic tissue from diabetic mice was performed. The experiment used eight-to-ten-week-old male C57BL/6 mice, divided into three groups of eight: diabetic, diabetic Fer-1-treated, and untreated control animals.

Diabetes was induced with multiple low doses of STZ at forty milligrams per kilogram for five consecutive days, from days one through five. Fer-1 was administered at one milligram per kilogram from day one to day twenty-one.

STZ and Fer-1 injections were administered three hours apart, and the control group received the diluents in the same amount. Blood and pancreas samples were collected for biochemical or microscopic analyses. Immunohistochemical or immunofluorescence staining determined the expression and localization of insulin, glucagon, PDX-1, 4-HNE, Nrf2, and the downstream targets GPX4, xCT, HO-1, and PRDX-2 in the endocrine pancreas.

A comparative analysis of serial tissue sections immunostained against insulin and glucagon, called the mirror technique, analyzed the localization of alpha and beta cells. For quantification, DAB images were used to determine mean grayscale values of islets per group, while the beta-cell and alpha-cell ratio was calculated by counting insulin- and glucagon-positive cells in islets.

Figure one links diabetic pancreatic injury with altered endocrine function and tissue structure. Compared with controls, diabetic animals show disrupted glucose and insulin measures, smaller islets, increased fibrosis, fewer insulin-positive beta cells, more glucagon-positive alpha cells, and sharply reduced PDX-1 staining.

Across the corresponding graphs and micrographs, Fer-one treatment shifts these features toward the control pattern, including stronger insulin and PDX-1 immunopositivity, which matters because PDX-1 supports beta-cell identity and insulin production. At day twenty-two, mean serum glucose and insulin levels were significantly altered in diabetic animals.

Concurrent Fer-1 treatment slightly lowered blood glucose toward the control value and significantly increased insulin above the diabetic-group value. A decrease in mean islet size was less pronounced in Fer-1-treated diabetic animals than in untreated diabetic animals.

Fibrosis around and inside islets also tended to decline toward the control level of collagen depositions with Fer-1 treatment. Figure two tracks several signs of pancreatic injury across control, diabetic, and Fer-one-treated diabetic animals. TUNEL and PI imaging shows stronger DNA-fragmentation staining in diabetic islet nuclei, with quantification in panel B, while four-HNE staining and its quantification report lipid peroxidation in the islets.

Sudan III identifies lipofuscin, and Pearl’s staining reveals iron-loaded phagocyte-like cells in diabetic exocrine pancreas; these features are reported as reduced after Fer-one treatment, linking the treatment to less apparent cellular damage and iron accumulation. Pancreatic four-HNE immunopositivity was particularly pronounced in the islets of Langerhans and blood vessels.

Increased four-HNE immunopositivity of islets was decreased by Fer-1 treatment, confirming lower lipid peroxidation in the pancreas of these animals. Numerous phagocyte-like cells with iron-containing phagosomes or lysosomes were detectable in the pancreas of diabetic animals, while their presence was rarely detectable in Fer-1-treated diabetic animals.

This indicates increased phagocytic activity in the pancreas of diabetic animals, which probably serves to ingest and remove dead islet cells. Figure three compares antioxidant and ferroptosis-related markers in pancreatic islets from control, diabetic, and Fer-one-treated diabetic animals.

The images and quantification show diabetes-associated changes in Nrf-two, GPX-four, HO-one, PRDX-two, and xCT, with xCT colocalized against insulin to assess beta cells; Fer-one treatment is accompanied by increased immunopositivity, including more Nrf-two-positive nuclei. These findings matter because they link diabetes-related beta-cell loss with altered antioxidant defenses and their treatment-associated restoration.

In diabetic animals, Nrf2 immunopositivity of islet cells decreased. Fer-1 treatment caused a sharp increase in Nrf2 immunopositivity that exceeded control level, including more Nrf2-positive nuclei. GPX4 immunopositivity was weak in control islets, with somewhat higher signal in rim cells.

In contrast, the diabetic Fer-1 group showed strong immunopositivity throughout the pancreatic endocrine tissue. The differences in islet immunopositivity to GPX4 among the groups were confirmed by quantitative analysis. Figure four summarizes how beta-cell ferroptosis may contribute to type one diabetes and how ferrostatin-one modifies this pathway.

In the type one diabetes panel, reduced Nrf2 and downstream protective markers accompany oxidative stress, lipid peroxidation, DNA fragmentation, and ferroptosis, alongside changes in islet structure and beta-cell function. The type one diabetes plus ferrostatin-one panel depicts restoration of Nrf2-related defenses and reduced ferroptosis-associated processes, supporting the authors’ proposed protective mechanism in pancreatic beta cells.

The decrease in Nrf2, together with its downstream targets GPX4, xCT, and HO-1, followed by accumulation of lipid peroxides in islet cells, suggests ferroptosis as an important mode of beta-cell removal in type one diabetes. The participation of PRDX-2 downregulation in ferroptosis of islet cells is demonstrated for the first time in diabetes, while the PRDX family is already shown to protect different cells from ferroptosis.

The results confirm an important contribution of beta-cell ferroptosis to the development and pathogenesis of type one diabetes through modulation of Nrf2 and its downstream targets. They also suggest antiferroptotic agents as a promising therapeutic strategy for the prevention and treatment of diabetes.

The study links beta-cell ferroptosis to type 1 diabetes through lipid peroxidation and weakened Nrf2 defenses, while ferrostatin-1 improved several pancreatic measures and points toward antiferroptotic treatment.